Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$709K Buy
2,819
+9
+0.3% +$1.94K 0.36% 64
2026
Q1
$611K Sell
2,810
-80
-3% -$17.7K 0.33% 64
2025
Q4
$660K Buy
2,890
+20
+0.7% +$4.56K 0.38% 59
2025
Q3
$664K Sell
2,870
-33
-1% -$6.72K 0.42% 56
2025
Q2
$539K Buy
2,903
+1,242
+75% +$231K 0.37% 61
2025
Q1
$348K Buy
1,661
+37
+2% +$7.19K 0.28% 67
2024
Q4
$289K Buy
1,624
+8
+0.5% +$1.47K 0.23% 73
2024
Q3
$319K Buy
1,616
+6
+0.4% +$1.12K 0.26% 68
2024
Q2
$276K Buy
1,610
+12
+0.8% +$1.99K 0.23% 74
2024
Q1
$291K Sell
1,598
-20
-1% -$3.45K 0.26% 69
2023
Q4
$251K Buy
+1,618
New +$236K 0.24% 82
2021
Q4
$211K Buy
+1,558
New +$184K 0.22% 72

Other funds holding ABBV

Finivi Inc's ABBV Position: Q2 2026 in Review

Finivi Inc increased its AbbVie (ABBV) stake by 0.32% in Q2 2026, buying an estimated $1.94K and bringing the position to 2,819 shares worth $709K. The position accounts for 0.36% of the portfolio, ranked #64.

Finivi Inc first reported a position in ABBV in Q4 2021 and has held it in 12 quarters since. 4,148 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Finivi Inc held 2,819 shares of AbbVie worth $709K as of Q2 2026.
  • Finivi Inc bought 9 AbbVie shares in Q2 2026, an estimated $1.94K.
  • AbbVie made up 0.36% of Finivi Inc's portfolio in Q2 2026, its #64 holding.
  • Finivi Inc first reported a position in AbbVie in Q4 2021 and has held it in 12 quarters since.
  • 4,148 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Finivi Inc's 13F filing for Q2 2026, filed 9 Jul 2026.